Table 4.
Mean (standard deviation) of outcomes by treatment group and study phase
| Intervention period |
Follow-up period |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Incentive Voucher with Coaching | Medication Coaching Alone | Incentive Voucher with Coaching | Medication Coaching Alone | ||||||
| Adherence by MEMS on time openings (%) | 77.6 | (17.5) | 55.5 | (23.1) | p<.001 | 66.0 | (23.9) | 53.1 | (29.2) |
| Adherence by pill count (%) | 85.9 | (11.4) | 75.4 | (21.3) | p<.05 | 80.9 | (18.3) | 78.4 | (28.4) |
| Adherence by self-report (%) | 87.3 | (14.0) | 68.7 | (17.7) | p<.001 | 80.6 | (21.2) | 71.6 | (25.5) |
| Plasma HIV-1 RNA (copies) [median] | 6,880 | [0] | 5,550 | [0] | 15,933 | [0] | 2,908 | [0] | |
| Viral load controlled (% at last visit) | 61.8 | 68.8 | 67.7 | 60.0 | |||||
| CD4+ (Cells/UL) | 302 | (194) | 314 | (165) | 324 | (216) | 360 | (195) | |
| SF-36 physical health summary score | 39.7 | (8.7) | 35.2 | (8.1) | 37.2 | (10.0) | 35.3 | (9.5) | |